According to GlobalData, QIASTAT-DX is one of 160 product lines sold in the US respiratory disease tests market; these product lines are sold by 75 different manufacturers. The average selling price for QIASTAT-DX increased in hospitals, decreased in health systems, and decreased outside of hospital facilities in 2022. The price of the QIASTAT-DX device can be viewed in GlobalData’s micro pricing report and can be retrieved according to purchase date, facility type, bed size, and geographical region. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Respiratory Disease Tests - Qiagen NV - QIASTAT-DX

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches.

In addition, the final selling pricing of medical devices is also impacted by the discounting policy of the manufacturer. Companies such as Qiagen apply discounts for their devices based on their internal business strategy, inventory control, and monthly or quarterly sales targets. In addition, sale location can also affect the final selling price of a device, both in terms of geographical region and facility type. Prices for the same medical device often vary in hospitals and health systems versus outside of hospital facilities, for example if high volume healthcare institutions can negotiate discounts or rebates based on large purchase sizes.

Qiagen overview

Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company’s sample technologies help isolate and process DNA, RNA, and proteins from samples such as blood, tissue and other materials; assay technologies to identify the genetic information of a pathogen in a tumor; bioinformatics solutions to analyze and interpret genomic data; and solutions to automate the use of consumables into efficient molecular testing workflows. It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical and biotechnology and life sciences research markets. The company offers products directly and also through a network of independent distributors. It has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Qiagen is headquartered in Venlo, the Netherlands.

For a complete picture of QIASTAT-DX, Respiratory Disease Tests pricing in the US, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.